Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis

Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis

Abstract Introduction Adherence to disease-modifying therapies is key for achieving optimal outcomes in multiple sclerosis (MS). Diroximel fumarate (DRF) is an oral fumarate approved for treatment of relapsing forms of MS. It has the same pharmacologically active metabolite as dimethyl fumarate (DMF...

Full description

Bibliographic Details
Main Authors: Brittney Lager, Jacob Liseno, Ivan Božin, Sarah M. England, Sai L. Shankar, Jason P. Mendoza, James B. Lewin
Format: Article
Language:English
Published: Adis, Springer Healthcare 2022-11-01
Series:Neurology and Therapy
Subjects:
Adherence
Dimethyl fumarate
Diroximel fumarate
Gastrointestinal side effects
Multiple sclerosis
Real-world treatment
Online Access:https://doi.org/10.1007/s40120-022-00413-0

Internet

https://doi.org/10.1007/s40120-022-00413-0

Similar Items